



PTO/SB/088 (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|---------------------|------------------------|----------------------|
| Substitute for form 1449/PTO | | Complete if Known | | | |
| SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 10/633,699 | | |
| | | Filing Date | August 5, 2003 | | |
| | | First Named Inventor | Pablo UMANA | | |
| | | Art Unit | 1633 | | |
| | | Examiner Name | Riggins, Patrick S. | | |
| Sheet | 1 | of | 1 | Attorney Docket Number | 1975.0010004/TJS/T-M |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published | T ² |
| MB | AT51 | Edge, C.J., <i>et al.</i> , "The conformational effects of N-linked glycosylation," <i>Biochem. Soc. Trans.</i> 21:452-455, Portland Press (1993) | |
| | AR52 | Jefferis, R. and Lund, J., "Glycosylation of Antibody Molecules: Structural and Functional Significance," <i>Chem. Immunol.</i> 65:111-128, Karger (January 1997) | |
| | AS52 | Jefferis, R., <i>et al.</i> , "Effector mechanisms activated by human IgG subclass antibodies: clinical and molecular aspects," <i>Ann. Biol. Clin.</i> 52:57-65, John Libbey Eurotext (1994) | |
| | AT52 | Jefferis, R., <i>et al.</i> , "IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation," <i>Immunol. Rev.</i> 163:59-76, Munksgaard (June 1998) | |
| | AR53 | Nakamura, K. <i>et al.</i> , "Chimeric Anti-Ganglioside G _{M2} Antibody with Antitumor Activity," <i>Cancer Research</i> 54:1511-1516, American Association for Cancer Research (1994) | |
| | AS53 | Routier, F.H. <i>et al.</i> , "The glycosylation pattern of a humanized IgG1 antibody (D1.3) expressed in CHO cells," <i>Glycoconjugate J.</i> 14:201-207, Chapman & Hall (February 1997) | |
| | AT53 | Shitara, K., <i>et al.</i> , "A new vector for the high level expression of chimeric antibodies in myeloma cells," <i>J. Immunol. Methods</i> 167:271-278, Elsevier Science (1991) | |
| | AR54 | Standley, S. and Baudry, M., "The role of glycosylation in ionotropic glutamate receptor ligand binding, function, and trafficking," <i>Cell. Mol. Life Sci.</i> 57:1508-1516, Birkhäuser Verlag (October 2000) | |
| | AS54 | Standley, P., <i>et al.</i> , "CHO cells provide access to novel N-glycans and developmentally regulated glycosyltransferases," <i>Glycobiol.</i> 6:695-699, Oxford University Press (1996) | |
| MB | AT54 | Youakim, A. and Shur, B.D., "Alteration of Oligosaccharide Biosynthesis by Genetic Manipulation of Glycosyltransferases," <i>Ann. N.Y. Acad. Sci.</i> 745:331-335, New York Academy of Sciences (1994) | |

555945_1.DOC

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Michael Burkhart/ | Date Considered | 10/25/2006 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.